Both a pharmacological inhibition of PERK and its selective deletion within the myeloid cell lineage resulted in enhanced antitumor immunity and slowed disease progression across multiple cancer models, and this protective activity was associated with the repression of NRF2 and upregulation of STING signaling in myeloid cells (101). Here, EIF2AK3 is linked to cancer.